Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?

J. Remon, L. E. Hendriks, C. Cabrera, N. Reguart, B. Besse*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Original languageEnglish
Pages (from-to)47-58
Number of pages12
JournalCancer Treatment Reviews
Volume71
DOIs
Publication statusPublished - Dec 2018

Keywords

  • Immunotherapy
  • EGFR
  • ALK
  • ROS1
  • BRAF
  • Advanced non-small cell lung cancer
  • IMMUNE CHECKPOINT INHIBITORS
  • DABRAFENIB PLUS TRAMETINIB
  • LIGAND 1 EXPRESSION
  • OPEN-LABEL
  • PD-L1 EXPRESSION
  • MOLECULAR CHARACTERISTICS
  • 1ST-LINE TREATMENT
  • ANTITUMOR-ACTIVITY
  • HER2 MUTATION
  • STAGE IV

Cite this